P944 Ustekinumab in refractory Ulcerative Colitis: single-center, real-world experience

C M Herrera De Guise,L F Mayorga Ayala,V Robles Alonso,X Serra Ruiz,E Céspedes Martínez,E Lastiri Gonzalez,Z Pérez Martínez,E Oller Jimenez,F Casellas,N Borruel Sainz

DOI: https://doi.org/10.1093/ecco-jcc/jjad212.1074

2024-01-01

Journal of Crohn's and Colitis

Abstract:Abstract Background Ustekinumab, an anti-interleukin 12/23 agent, was approved by the European Medicines Agency in 2019 as a treatment for moderate-to-severe ulcerative colitis (UC). Limited real-world data is available regarding the utilization of ustekinumab in UC, particularly medication persistence and escalation, which are indicators of medication performance in real-world settings. Our aim was to describe our experience with ustekinumab in refractory UC patients. Methods This was an observational single-center study on UC patients who received at least one intravenous dose of ustekinumab 16 weeks before data analysis due to active UC (Simple clinical colitis activity index (SCCAI)>5). Data regarding disease activity prior to and post-induction were analyzed. Patients were followed up until the last ustekinumab administration. Clinical response to therapy was assessed at 16, 24,52 weeks, and the end of follow-up. Response was defined as SCCAI<4, and remission as SCCAI≤2. Dose adjustment or IV maintenance was considered part of the treatment regimen. Patients who discontinued ustekinumab due to lack of therapeutic effect or worsening of UC were considered failures. When available, colonoscopy data was analyzed. Results Forty-seven patients who received ustekinumab for refractory UC were included. Thirty-eight percent were female, and 34% were former smokers. Median age was 46 [37.5-61.5]; 62% had extensive disease, and 15% had perianal disease. Ninety-three percent received at least one biologic before ustekinumab, and 24% had received a JAK inhibitor. Thirty-eight patients required dose escalation, and 11 were on maintenance IV. Clinical response at week 16 was achieved in 74% and remission in 46%. At 24 and 52 weeks, 65% and 61% were in remission, respectively. At the end of follow-up, 59% of patients had endoscopic remission (Endoscopic Mayo score ≤ 1). Sixty percent continued treatment during a mean follow-up of 12 months [6-21]. No variable was associated with risk of discontinuation. No serious adverse events were reported. Discontinuation of treatment was due to treatment failure in all cases. Conclusion Ustekinumab was effective for induction and maintenance in our cohort of UC patients, although a significant proportion required dose escalation. Drug persistence was higher than 50% during the follow-up. The safety profile of ustekinumab was similar to that in controlled studies and other real-world studies.

gastroenterology & hepatology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is the effectiveness and safety of using ustekinumab to treat refractory ulcerative colitis (UC) in the real world. Ustekinumab is an antibody drug targeting interleukin 12/23 (IL - 12/23) and was approved by the European Medicines Agency for the treatment of moderate - to - severe UC in 2019. However, the data on its effectiveness in actual clinical applications and continuous use are relatively limited. Therefore, this study aims to describe the experience of using ustekinumab in refractory UC patients in a center, especially to evaluate the efficacy of the drug, the need for dose adjustment, and the safety of long - term use.

Specifically, the study focused on the following aspects:
1. **Efficacy evaluation**: The clinical response and remission of patients were evaluated by the Simple Clinical Colitis Activity Index (SCCAI), with a response defined as SCCAI < 4 and remission as SCCAI ≤ 2.
2. **Dose adjustment**: Record the proportion of patients requiring dose increase or intravenous maintenance treatment.
3. **Drug persistence**: Track the time that patients continue to use ustekinumab and evaluate the discontinuation of the drug due to ineffective treatment or UC deterioration.
4. **Safety**: Monitor adverse events during the treatment process.

The results of the study indicate that ustekinumab is effective in inducing and maintaining the treatment of refractory UC, although a considerable number of patients require dose adjustment. The continuous use rate of the drug exceeds 50% during the follow - up period, and no serious adverse events were reported. These findings support the effectiveness and safety of ustekinumab in actual clinical applications.